Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led ...

More information: Heidi L. Moline et al, Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024, JAMA Pediatrics (2024). DOI: 10.1001 ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sanofi Healthcare India to conduct a Phase ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

The price you pay for Beyfortus may depend on factors such as your child’s dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Beyfortus.

Three-quarters of infants were exposed to the maternal RSV vaccine or nirsevimab during their first RSV season. Younger mothers and Black mothers were less likely to receive the maternal vaccine.

Jacobson, M.D., M.P.H., from Kaiser Permanente Northern California in Oakland, and colleagues investigated the uptake of RSVpreF among pregnant women at 32 to 36 weeks of gestation and nirsevimab ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.